📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC). (2019)

First Author: Woodcock V

Attributed to: MRC and DfID contribution to jointly funded rapid response strategic award funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.2019.37.7_suppl.406

Publication URI: http://dx.doi.org/10.1200/jco.2019.37.7_suppl.406

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 7_suppl